Hepion Pharmaceuticals, Inc. (HEPA): Nasdaq/NYSE listing notice — Hepion receives Nasdaq delisting notice as bid price falls below $0.10 for 10 days

Hepion Pharmaceuticals, Inc.

Stock closed below $0.10 for 10 consecutive business days triggering the Low Priced Stocks Rule.
If no appeal by March 25 and $20,000 fee, delisting from Nasdaq Capital Market starts March 27, 2025.
Company intends to appeal but cannot guarantee success in continuing listing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5810(c)(3)(A)(iii)

Exact text from the filing

March 18, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the bid price for the Company’s common stock (the “ Common Stock ”), for the last 10 consecutive business days, had closed below $0.10 per share and, as a result, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). As such, unless the Company requests an appeal of Nasdaq’s determination to delist the Company’s common stock from The Na

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-011038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.